Such work is important in order to ensure the thyroidal safety of Nrf2-activating compounds that are being developed for use in other indications, and it might also facilitate the development of new drugs for the prevention and the treatment of both benign thyroid diseases, and thyroid carcinomas. This evidence concerns the gene NFE2L2 and thyroid gland carcinoma.